 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "HOT-17" – news ·newspapers ·books ·scholar ·JSTOR(July 2019) |
 | |
| Names | |
|---|---|
| Preferred IUPAC name 2-{4-[(Butan-2-yl)sulfanyl]-2,5-dimethoxyphenyl}-N-hydroxyethan-1-amine | |
| Other names 2-[4-(Isobutylthio)-2,5-dimethoxyphenyl]ethanaminol | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C14H23NO3S | |
| Molar mass | 285.40 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
HOT-17 (2,5-dimethoxy-4-(β-isobutylthio)-N-hydroxyphenethylamine) is apsychedelicphenethylamine of the2C family. It was synthesized byAlexander Shulgin and reported in his bookPiHKAL.[1]
HOT-17's full chemical name is 2-[4-(2-isobutylthio)-2,5-dimethoxyphenyl-N-hydroxyethanamine. It hasstructural properties similar to2C-T-17 and to other drugs in the HOT- series, with the most closely related compounds beingHOT-2 andHOT-7.
The dosage range of HOT-17 is typically 70-120mg and its duration is approximately 12–18 hours according to Shulgin.[1] HOT-17 produces time distortion and generalpsychedelia. It also has little to no body load.
